{"transactions":[{"id":3481035,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-21T16:02:52.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the  next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":6.12,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-19-037000","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000110465919037000/a4.xml","form_type":"4"}},{"id":3576371,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-27T16:29:07.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":4410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the Option vest on the the date prior to the day of the Company's 2019 annual meeting of stockholders. In accordance with the internal policies of Clarus Ventures, the options received by Dr. Galakatos must be held for the benefit of Clarus Ventures and its affiliates."}],"balance_after":4410,"derivative":{"exercise_price":23.34,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":4410},"source":{"system":"sec-edgar","filing":"0001401708-19-000107","document":"wf-form4_155371853257568.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000140170819000107/wf-form4_155371853257568.xml","form_type":"4"}},{"id":3690512,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-22T16:57:13.000Z","date":"2019-01-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on January 1, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":15000,"derivative":{"exercise_price":5.66,"expiration_date":"2029-01-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-004766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919119004766/doc4.xml","form_type":"4"}},{"id":3800833,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":8552024,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412583},"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800832,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":6702213,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323341},"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800831,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":361829},"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800830,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":453395,"price":15,"value":6800925.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1623405,"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800829,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":412583,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1170010,"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800828,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":323341,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":685170,"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3800827,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:38:44.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":361829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. The Reporting Person, a director of the Issuer, is a managing director of Clarus III GP LLC. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Reporting Person disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":361829,"source":{"system":"sec-edgar","filing":"0001209191-18-053536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252522/000120919118053536/doc4.xml","form_type":"4"}},{"id":3811530,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2018-09-19T16:45:25.000Z","date":"2018-09-17","kind":"other","acquired":false,"shares":162408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus Lifesciences II, L.P. (\"Clarus\"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest.  Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":8.448,"exercise_date":"2011-11-01","expiration_date":"2018-11-01","underlying":"Common Stock","underlying_shares":162408},"source":{"system":"sec-edgar","filing":"0001401708-18-000121","document":"wf-form4_153738990634404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000140170818000121/wf-form4_153738990634404.xml","form_type":"4"}},{"id":3811529,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-19T16:45:25.000Z","date":"2018-09-17","kind":"sale","acquired":false,"shares":85823,"price":15.99,"value":1372309.77,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 17, 2018 Clarus Lifesciences II, L.P. (\"Clarus\") exercised warrants to purchase 162,408 shares of the Company's common stock for $8.448 per share. Clarus paid the exercise price on a cashless basis, resulting in the Company's withholding of 85,823 of the warrant shares to pay the exercise price and issuing to Clarus the remaining 76,585 shares."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person, a member of the board of directors, in favor of the underwriters of the Company's public offering in July 2018 (the \"Lock-up\"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up. No shares were sold by the Reporting Person or Clarus in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus Lifesciences II, L.P. (\"Clarus\"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest.  Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest."}],"balance_after":4036025,"source":{"system":"sec-edgar","filing":"0001401708-18-000121","document":"wf-form4_153738990634404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000140170818000121/wf-form4_153738990634404.xml","form_type":"4"}},{"id":3811528,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-19T16:45:25.000Z","date":"2018-09-17","kind":"other","acquired":true,"shares":162408,"price":8.448,"value":1372022.784,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus Lifesciences II, L.P. (\"Clarus\"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest.  Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest."}],"balance_after":4121848,"source":{"system":"sec-edgar","filing":"0001401708-18-000121","document":"wf-form4_153738990634404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000140170818000121/wf-form4_153738990634404.xml","form_type":"4"}},{"id":3878867,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1922682},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878866,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":755780,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":755780},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878865,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938489},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878864,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":200000,"price":16,"value":3200000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3816951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878863,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3616951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878862,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":1694269,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878861,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":938489,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":938489,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":4111251,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T18:18:52.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":10168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the Option vest on the one year anniversary of January 1, 2018. The vesting of shares subject to the Option will accelerate in full upon a \"change in control\" as defined in the 2013 Equity Incentive Plan.  In accordance with the internal policies of Clarus Ventures, the options received by Dr. Galakatos must be held for the benefit of Clarus Ventures and its affiliates."}],"balance_after":10168,"derivative":{"exercise_price":7.47,"expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":10168},"source":{"system":"sec-edgar","filing":"0001401708-18-000010","document":"wf-form4_151502151810363.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000140170818000010/wf-form4_151502151810363.xml","form_type":"4"}},{"id":4184776,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":180881},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184775,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date is not relevant to the conversion of these securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3389105},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184774,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":180881,"price":7,"value":1266167.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3569986,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184773,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3389105,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4186578,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":6,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-13T19:04:52.000Z","date":"2017-10-11","kind":"other","acquired":true,"price":1259269.79,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were originally acquired from the Issuer on September 6, 2017; however, the conversion price was set upon the pricing of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The convertible promissory note is directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"derivative":{"exercise_price":7,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-038670","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038670/doc1.xml","form_type":"4"}},{"id":4502316,"issuer":{"id":15988,"kind":"organization","name":"NanoString Technologies Inc","symbol":"NSTG"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-04T18:06:10.000Z","date":"2017-01-01","kind":"grant","acquired":true,"shares":8611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the Option vest on the one year anniversary of January 1, 2017. The vesting of shares subject to the Option will accelerate in full upon a \"change in control\" as defined in the 2013 Equity Incentive Plan. In accordance with the internal policies of Clarus Ventures, the options received by Dr. Galakatos must be held for the benefit of Clarus Ventures and its affiliates."}],"balance_after":8611,"derivative":{"exercise_price":22.3,"expiration_date":"2026-12-31","underlying":"Common Stock","underlying_shares":8611},"source":{"system":"sec-edgar","filing":"0001209191-17-001339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401708/000120919117001339/doc4.xml","form_type":"4"}},{"id":4592592,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":1,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182000,"kind":"person","name":"SIMON NICHOLAS J III","position":2,"cik":"0001221595","reported_name":"SIMON NICHOLAS J III","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":3,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}}],"security":"Common Stock","published_at":"2016-09-29T18:04:35.000Z","date":"2016-09-27","kind":"other","acquired":false,"shares":1229902,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by the reporting persons, without consideration to their respective limited partners and members."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were distributed as follows: 1,023,819 shares by MPM Bioventures III-QP, L.P. (\"BV III QP\"), 68,835 shares by MPM BioVentures III, L.P (\"BV III\"), 19,815 shares by MPM Asset Management Investors 2003 BVIII LLC (\"AM 2003\"), 30,911 shares by MPM BioVentures III Parallel Fund, L.P. (\"BV Parallel\") and 86,522 shares by MPM BioVentures III GmbH & Co. Beteiligungs KG (\"BV KG\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by the reporting persons, without consideration to their respective limited partners and members."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The shares are held as follows: 2,047,635 shares by BV III QP, 137,671 shares by BV III, 39,630 shares by AM 2003, 61,823 shares by BV Parallel and 173,045 shares by BV KG."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures III GP, L.P. (\"MPM III GP\") and MPM BioVentures III LLC (\"MPM III LLC\") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG.  Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are members of MPM III LLC and AM 2003.  Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein."}],"balance_after":2459804,"source":{"system":"sec-edgar","filing":"0001209191-16-143186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919116143186/doc4.xml","form_type":"4"}}]}